Lexicon Pharmaceuticals, Inc. (LXRX)

Market Cap	732.97M +467.8%
Revenue (ttm)	49.80M +60.2%
Net Income	-50.34M
EPS	-0.14
Shares Out	423.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	429,253
Open	1.770
Previous Close	1.760
Day's Range	1.731 - 1.800
52-Week Range	0.470 - 1.840
Beta	0.95
Analysts	Strong Buy
Price Target	4.15 (+139.88%)
Earnings Date	May 12, 2026

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart fail...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: LXRX
• Website: https://www.lexpharma.com

Financial Performance

In 2025, Lexicon Pharmaceuticals's revenue was $49.80 million, an increase of 60.24% compared to the previous year's $31.08 million. Losses were -$50.34 million, -74.88% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for LXRX stock is "Strong Buy." The 12-month stock price target is $4.15, which is an increase of 139.88% from the latest price.

Price Target

$4.15

(139.88% upside)

Analyst Consensus: Strong Buy